A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasisCapsule Summary

Background: DMB-3115 is a biosimilar to Stelara (hereinafter referred to as ustekinumab). Objectives: To evaluate the clinical similarity of DMB-3115 with ustekinumab in patients with moderate-to-severe plaque psoriasis. Methods: In this phase 3, randomized, double-blind, parallel-arm study, adults...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Kamelia Vekovska, MD, Beata Imko-Walczuk, PhD, Martin Tichý, PhD, Zoe Diana Draelos, MD, Petra Cetkovska, PhD, Phoebe Rich, MD, Jolanta Weglowska, MD
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-02-01
Serie:	JAAD International
Soggetti:	biologics biosimilar psoriasis randomized clinical trial ustekinumab
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2666328725001130
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!